8
Catalog #500023
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500023 | 1 mg | $200.00 | ||
| 500023 | 5 mg | $600.00 | ||
| 500023 | 20 mg | $1,250.00 |
Eculizumab biosimilar is a humanized IgG2/4 monoclonal antibody that specifically targets complement protein C5, preventing its cleavage into C5a and C5b. As a biosimilar to the reference biologic Eculizumab, this antibody is designed for complement system research, autoimmune disease studies, and inflammatory disorder investigations.
| Clone | Eculizumab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG2/4 |
| Recommended Isotype Control | Human IgG2 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 6.0 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | Human C5 |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |